Diclofenac Sodium and Misoprostol Delayed-Release Tablets

<table>
<thead>
<tr>
<th>Type of Posting</th>
<th>Notice of Intent to Revise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posting Date</td>
<td>29–Mar–2019</td>
</tr>
<tr>
<td>Targeted Official Date</td>
<td>To Be Determined, Revision Bulletin</td>
</tr>
<tr>
<td>Expert Committee</td>
<td>Chemical Medicines Monographs 3</td>
</tr>
</tbody>
</table>

In accordance with section 7.04 (c) of the 2015–2020 Rules and Procedures of the Council of Experts and the Pending Monograph Guideline, this is to provide notice that the Chemical Medicines Monographs 3 Expert Committee intends to revise the Diclofenac Sodium and Misoprostol Delayed-Release Tablets monograph.

Based on the supporting data received from a manufacturer awaiting FDA approval, the Expert Committee proposes to add Dissolution Test 2 to the monograph. Labeling information has been incorporated to support the inclusion of Dissolution Test 2.

- Dissolution Test 2 was validated using the Zorbax SB-Phenyl brand of L11 column. The typical retention time for misoprostol is about 8 min.

The proposed revision is contingent on FDA approval of a product that meets the proposed monograph specifications. The proposed revision will be published as a Revision Bulletin and an official date will be assigned to coincide as closely as possible with the FDA approval of the associated product.

See below for additional information about the proposed text.¹

Should you have any questions, please contact Behnaz Almasi, Scientific Liaison to the Chemical Medicines Monographs 3 Expert Committee (301-692-3412 or ba@usp.org).

¹ This text is not the official version of a USP–NF monograph and may not reflect the full and accurate contents of the currently official monograph. Please refer to the current edition of the USP–NF for official text.

USP provides this text to indicate changes that we anticipate will be made official once the product subject to this proposed revision under the Pending Monograph Program receives FDA approval. Once FDA approval is granted for the associated revision request, a Revision Bulletin will be posted that will include the changes indicated herein, as well as any changes indicated in the product's final approval, combined with the text of the monograph as effective on the date of approval. Any revisions made to a monograph under the Pending Monograph Program that are posted without prior publication for comment in the Pharmacopeial Forum must also meet the requirements outlined in the USP Guideline on Use of Accelerated Processes for Revisions to the USP–NF.
Diclofenac Sodium and Misoprostol Delayed-Release Tablets

**DEFINITION**

Diclofenac Sodium and Misoprostol Delayed-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of diclofenac sodium (C₁₅H₁₈Cl₂NO₄) and NLT 90.0% and NMT 110.0% of the labeled amount of misoprostol (C₂₂H₃₆O₆).

**IDENTIFICATION**

**A. ULTRAVIOLET ABSORPTION** (197U)

**Misoprostol**

Diluent: Methanol and water (4:1)

**Standard solution:** 16 µg/mL of USP Misoprostol RS in *Diluent*.

**Sample solution:** Gently break up one by one a quantity of Tablets equivalent to 0.4 mg of misoprostol, and remove the inner diclofenac layers. Transfer the diclofenac inner layers for Identification A, Diclofenac sodium. Transfer the outer misoprostol layers to a 25-mL volumetric flask. Add about 15 mL of *Diluent*, shake for 30 min, dilute with *Diluent* to volume, and mix well. Transfer a portion of the solution into a glass centrifuge tube, and centrifuge for 10 min under refrigerated conditions (10°C). Use the supernatant.

**Blank:** *Diluent*

**Cell:** 1 cm

**Acceptance criteria:** Meet the requirements

**Diclofenac sodium**

**Standard solution:** 0.1 mg/mL of USP Diclofenac Sodium RS in methanol

**Sample solution:** Transfer the diclofenac inner layers reserved from Identification A, Misoprostol, to a 100-mL volumetric flask. Add about 60 mL of methanol, shake for 10 min, dilute with methanol to volume, and mix well. Further dilute a suitable volume of the solution to obtain a solution containing about 0.1 mg/mL of diclofenac sodium, based on the label claim. Pass a portion of the solution through a polytetrafluoroethylene (PTFE) with glass microfiber (CMF) filter of 0.45-µm pore size. Discard the first few milliliters of the filtrate, and use the filtrate.

**Blank:** Methanol

**Cell:** 0.05 cm

**Acceptance criteria:** Meet the requirements

**B. Misoprostol:** The retention time of the misoprostol peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for Misoprostol.

**Diclofenac sodium:** The retention time of the diclofenac peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for Diclofenac Sodium.

**ASSAY**

** Misoprostol**

**Buffer:** Prepare 0.025 M monobasic potassium phosphate, pH 6.5, as follows. Adjust a solution containing 3.4 g/L of monobasic potassium phosphate in water with 1 N sodium hydroxide to a pH of 6.5.

**Mobile phase:** Acetonitrile and Buffer (45:55)

**Diclofenac Sodium**

**Buffer:** Mix equal volumes of 0.01 M phosphoric acid and 0.01 M monobasic sodium phosphate. If necessary, adjust with additional portions of the appropriate component to a pH of 2.5.

**Mobile phase:** Methanol and Buffer (70:30)

**Diluent:** Methanol and water (70:30)

**System suitability solution:** 20 µg/mL of diethyl phthalate, 8 µg/mL of USP Diclofenac Related Compound A RS, and 0.75 mg/mL of USP Diclofenac Sodium RS in *Diluent*

**Standard solution:** 0.75 mg/mL of USP Diclofenac Sodium RS in *Diluent*, using sonication as needed

**Sample stock solution:** Transfer a quantity of Tablets, equivalent to 1500 mg of diclofenac sodium, into a 1000-mL volumetric flask containing a magnetic stir bar. Add 700 mL of *Diluent*, and stir for 60 min or until the Tablets are completely disintegrated. Remove the stir bar, rinse it with *Diluent*, and sonicate the sample for 15 min.

**Standard solution:** 0.01 mg/mL of USP Misoprostol RS in *Mobile phase*, using sonication as needed

**Sample solution:** Nominal 0.01 mg/mL of misoprostol prepared as follows. Using a quantity of Tablets equivalent to 5 mg of misoprostol, place 1 Tablet at a time on its edge inside a well-folded piece of weighing paper. Tap very carefully the edge of the Tablet with a pestle to separate the Tablet into the outer and inner layers. Remove the inner core containing diclofenac sodium. Transfer the outer portions of the Tablets, containing misoprostol, into a 500-mL volumetric flask containing a magnetic stir bar, and add 250 mL of acetonitrile. Stir the flask for 1 h. Add 150 mL of water, and stir for an additional 30 min or until the Tablets are completely disintegrated. Remove the stir bar, rinse it inside the flask with water, dilute with water to volume, and mix well. Transfer a portion of the solution into a glass centrifuge tube, and centrifuge for 10 min under refrigerated conditions (10°C). Use the supernatant.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 200 nm

**Column:** 4.6-mm × 25-cm; 5-µm packing L10

**Temperatures**

**Autosampler:** 10°C

**Column:** 35°C

**Flow rate:** 1.0 mL/min

**Injection volume:** 80 µL

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Tailing factor:** NMT 2

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of misoprostol (C₂₂H₃₆O₆) in the portion of Tablets taken:

\[
\text{Result} = \left( \frac{r_u}{r_s} \right) \times \left( \frac{C_s}{C_U} \right) \times 100
\]

\[r_u = \text{peak response from the } \text{Sample solution}\]
\[r_s = \text{peak response from the } \text{Standard solution}\]
\[C_s = \text{concentration of USP Misoprostol RS in the \text{Standard solution} (mg/mL)}\]
\[C_U = \text{nominal concentration of misoprostol in the \text{Sample solution} (mg/mL)}\]

**Acceptance criteria:** 90.0%–110.0%

---

1 A suitable filter is available as GD/X Syringe Filter, Whatman, www.whatman.com, catalog no. 6874-2504.
the sample to cool to room temperature, dilute with Diluent to volume, and mix well.

**Sample solution**: Nominally 0.75 mg/mL of diclofenac sodium prepared as follows. Transfer 10.0 mL of the Sample stock solution into a 20-mL volumetric flask, and dilute with Diluent to volume. Pass a portion of the solution through a PTFE with GMF filter of 0.45-µm pore size, discarding the first few milliliters of the filtrate.

**Chromatographic system**
(See Chromatography (621), System Suitability.)

- **Mode**: LC
- **Detector**: UV 254 nm
- **Column**: 4.6-mm × 25-cm; 5-µm packing L7
- **Flow rate**: 1.0 mL/min
- **Injection volume**: 10 µL

**System suitability**

**Samples**: System suitability solution and Standard solution

[Note—The relative retention times for diethyl phthalate, diclofenac related compound A, and diclofenac are about 0.6, 0.7, and 1.0, respectively.]

- **Resolution**: NLT 2.2 between the diethyl phthalate and diclofenac related compound A peaks; NLT 6.5 between the diclofenac related compound A and diclofenac peaks, System suitability solution
- **Tailing factor**: NMT 2; Standard solution
- **Relative standard deviation**: NMT 2.0%; Standard solution

**Analysis**

**Samples**: Standard solution and Sample solution

Calculate the percentage of the labeled amount of diclofenac sodium (C$_{13}$H$_{18}$Cl$_2$NNaO$_3$) in the portion of Tablets taken:

$$\text{Result} = \left( \frac{r_i}{r_o} \right) \times \left( \frac{C_\text{S}}{C_\text{U}} \right) \times 100$$

$r_i$ = peak response from the Sample solution
$r_o$ = peak response from the Standard solution
$C_\text{S}$ = concentration of USP Diclofenac Sodium RS in the Standard solution (mg/mL)
$C_\text{U}$ = nominal concentration of diclofenac sodium in the Sample solution (mg/mL)

**Acceptance criteria**: 90.0%–110.0%

**PERFORMANCE TESTS**

**Change to read:**

- **Dissolution** (711)
  - Test 1 (RBD)
    - **Misoprostol**
      - Medium: Water; 500 mL, deaerated
      - Apparatus 2: 50 rpm
      - Time: 20 min
      - **Buffer**: Prepare as directed in the Assay for Misoprostol.
    - **Mobile phase**: Acetonitrile and Buffer (42:58)
    - **Standard stock solution**: Transfer 4 mg of USP Misoprostol RS into a 100-mL volumetric flask, add 20 mL of acetonitrile, and shake for about 15 min. If the outer misoprostol layers of the Tablets contain hypromellose, add a suitable amount of hypromellose to the flask to achieve the same final concentration of hypromellose in the Standard solution as expected in the Sample solution. Add 20 mL of water, and sonicate for about 2 min. Add water up to the neck of the flask, and allow the solution to cool to room temperature before the final dilution to volume.

**Standard solution**: About 0.0004 mg/mL of USP Misoprostol RS prepared as follows. Dilute 2.0 mL of the Standard stock solution with Medium to 200 mL.

**Sample solution**: Pass a portion of the solution under test through a suitable filter of 10-µm pore size.

**Chromatographic system**: Proceed as directed in the Assay for Misoprostol, except for Injection volume.

- **Injection volume**: 200 µL

**System suitability**

- **Sample**: Standard solution
- **Suitability requirements**
- **Tailing factor**: NMT 2
- **Relative standard deviation**: NMT 5.0%

**Analysis**

- **Samples**: Standard solution and Sample solution

Calculate the percentage of the labeled amount of misoprostol (C$_{19}$H$_{18}$O$_3$) dissolved:

$$\text{Result} = \left( \frac{r_i}{r_o} \right) \times \left( \frac{C_\text{S}}{C_\text{U}} \right) \times V \times 100$$

$r_i$ = peak response from the Sample solution
$r_o$ = peak response from the Standard solution
$C_\text{S}$ = concentration of USP Misoprostol RS in the Standard solution (mg/mL)
$C_\text{U}$ = label claim for misoprostol (mg/Tablet)
$V$ = volume of Medium, 500 mL

**Tolerances**: NLT 75% (Q) of the labeled amount of misoprostol (C$_{19}$H$_{18}$O$_3$) is dissolved.

**Diclofenac sodium**

Proceed as directed in Dissolution (711), Procedure, Apparatus 1 and Apparatus 2, Delayed-release dosage forms, Method A Procedure.

- **Acid stage medium**: 0.1 N hydrochloric acid; 750 mL, deaerated
- **Buffer stage medium**: After 2 h, add 250 mL of 0.2 M tribasic sodium phosphate to the Acid stage medium and, if needed, adjust with either 2 N hydrochloric acid or 2 N sodium hydroxide to a pH of 6.8.
- **Apparatus 2**: 100 rpm
- **Times**: 2 h for Acid stage; 45 min for Buffer stage
- **Buffer**: 0.025 M monobasic potassium phosphate buffer with a pH of 3.0 prepared as follows. Adjust a solution containing 3.4 g/L of monobasic potassium phosphate in water with phosphoric acid to a pH of 3.0.

**Mobile phase**: Acetonitrile and Buffer (60:40)

**Standard stock solution**: 0.68 mg/mL of USP Diclofenac Sodium RS, first dissolved in 0.1 N sodium hydroxide using about 10% of the final volume, and then diluted with water to volume.

**Chromatographic system**
(See Chromatography (621), System Suitability.)

- **Mode**: LC
- **Detector**: UV 276 nm
- **Column**: 4.6-mm × 15-cm; 5-µm packing L7
- **Flow rate**: 1.0 mL/min
- **Injection volume**: 10 µL

**Acid stage**

- **Acid stage standard solution**: 13.6 µg/mL of USP Diclofenac Sodium RS prepared as follows. Transfer 2.0 mL of the Standard stock solution to a 100-mL volumetric flask, and dilute with a mixture of 0.1 N hydrochloric acid and 5 N sodium hydroxide (900:20) to volume.

**Acid stage sample solution**: Run the test in Acid stage medium for 2 h. Withdraw a 10-mL aliquot, transfer it to a flask containing 1.0 mL of 1 N sodium
hydroxide, and mix well. Pass a portion of this solution through a suitable filter of 10-μm pore size.

**System suitability**

**Sample:** Acid stage standard solution

**Suitability requirements**

- Tailing factor: NMT 2
- Relative standard deviation: NMT 2.0%

**Analysis**

**Samples:** Acid stage standard solution and Acid stage sample solution

Calculate the percentage of the labeled amount of diclofenac sodium (C₁₄H₁₄Cl₂Na₂O₄) dissolved during the Acid stage:

\[
\text{Result} = \left( \frac{r_o}{r_s} \times \frac{C_s}{L} \right) \times V \times D \times 100
\]

- \( r_o \) = peak response from the Acid stage sample solution
- \( r_s \) = peak response from the Acid stage standard solution
- \( C_s \) = concentration of USP Diclofenac Sodium RS in the Acid stage standard solution (mg/mL)
- \( L \) = label claim for diclofenac sodium (mg/Tablet)
- \( V \) = volume of Acid stage medium, 750 mL
- \( D \) = dilution factor for the Acid stage sample solution, 1.1

**Tolerances:** NMT 10% of the labeled amount of diclofenac sodium (C₁₄H₁₄Cl₂Na₂O₄) is dissolved. The percentage of the labeled amount of diclofenac sodium dissolved at the time specified conforms to Dissolution (711), Acceptance Table 3.

**Buffer stage**

**Buffer stage standard solution:** 13.6 μg/mL of USP Diclofenac Sodium RS prepared as follows. Transfer 2.0 mL of the Standard stock solution to a 100-mL volumetric flask, and dilute with Buffer stage medium to volume.

**Buffer stage sample solution:** Pass a portion of the solution under test through a suitable filter of 10-μm pore size.

**System suitability**

- **Sample:** Buffer stage standard solution
- **Suitability requirements**
  - Tailing factor: NMT 2
  - Relative standard deviation: NMT 2.0%

**Analysis**

**Samples:** acid stage sample solution, Buffer stage standard solution, and Buffer stage sample solution

Calculate the percentage of the labeled amount of diclofenac sodium (C₁₄H₁₄Cl₂Na₂O₄) dissolved during the Buffer stage:

\[
\text{Result} = \left( \frac{r_o}{r_s} \times \frac{C_s}{L} \right) \times V \times (1/L) \times 100
\]

- \( r_o \) = peak response of misoprostol from the Sample solution
- \( r_s \) = peak response of misoprostol from the Standard solution
- \( C_s \) = concentration of USP Misoprostol RS in the Standard solution (mg/mL)
- \( L \) = label claim for misoprostol (mg/Tablet)
- \( V \) = volume of Medium, 500 mL

**Tolerances:** NLT 80% (Q) of the labeled amount of misoprostol (C₂₂H₃₈O₁₉) is dissolved. The percentage of the labeled amount of misoprostol dissolved at the time specified conforms to Dissolution (711), Acceptance Table 4.

**Test 2:** If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2.

**Misoprostol**

- **Medium:** Water; 500 mL
- **Apparatus 2:** 50 rpm
- **Time:** 15 min

**Solution A:** 24.5 g/L of phosphoric acid in water

**Mobile phase:** Acetonitrile, water, and Solution A (50: 50: 0.5)

**Standard stock solution:** 0.01 mg/mL of USP Misoprostol RS prepared as follows. Transfer 10 mg of USP Misoprostol RS into a 100-mL volumetric flask; add 10 mL of acetonitrile, and swirl the flask to disperse. If the outer misoprostol layers of the Tablets contain hypromellose, add a suitable amount of hypromellose to the flask to achieve the same final concentration of hypromellose in the Standard solution as expected in the Sample solution. Add about 60 mL of Diluent and sonicate to dissolve. Dilute with Diluent to volume. Further dilute 5.0 mL of this solution with Diluent to 50 mL.

**Standard solution:** 0.0004 mg/mL of USP Misoprostol RS in Medium from the Standard stock solution

**Sample solution:** Pass a portion of the solution under test through a PVDF filter of 0.45-μm pore size, discarding the first 5 mL of the filtrate.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

- **Detector:** UV 200 nm
- **Column:** 4.6-mm × 25-cm; 5-μm packing L11
- **Autosampler temperature:** 5°C
- **Flow rate:** 1 mL/min
- **Injection volume:** 100 μL

**System suitability**

**Sample:** Standard solution

**Suitability requirements**

- **Tailing factor:** NMT 2.0
- **Relative standard deviation:** NMT 5.0%

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of misoprostol (C₂₂H₃₈O₁₉) dissolved:

\[
\text{Result} = \left( \frac{r_o}{r_s} \right) \times C_s \times V \times (1/L) \times 100
\]

- \( r_o \) = peak response of misoprostol from the Sample solution
- \( r_s \) = peak response of misoprostol from the Standard solution
- \( C_s \) = concentration of USP Misoprostol RS in the Standard solution (mg/mL)
- \( V \) = volume of Medium, 500 mL
- \( L \) = label claim for misoprostol (mg/Tablet)

**Tolerances:** NLT 80% (Q) of the labeled amount of misoprostol (C₂₂H₃₈O₁₉) is dissolved.

**Diclofenac sodium**

- **Acid stage medium:** 0.1 N hydrochloric acid; 750 mL
- **Buffer:** 76.02 g/L of tribasic sodium phosphate deodecahydrate in water

---

© The United States Pharmacopeial Convention All Rights Reserved.
**Diclofenac**

**Buffer stage medium:** 0.1 N hydrochloric acid and Buffer (75:25). Adjust with either 2 N hydrochloric acid or 2 N sodium hydroxide to a pH of 6.8 ± 0.1; 1000 mL

**Apparatus 2:** 100 rpm

**Times**

- **Acid stage:** 2 h
- **Buffer stage:** 60 min

**Diluent:** Methanol and water (50:50)

**Acid stage**

- **Acid stage standard stock solution:** 0.75 mg/mL of USP Diclofenac Sodium RS in Diluent
- **Acid stage standard solution:** (L/10,000) mg/mL of USP Diclofenac Sodium RS in Buffer stage medium, where L is the label claim of diclofenac sodium in milligrams per Tablet

**Acid stage sample solution:** Run the test in Acid stage medium for 2 h. Withdraw 13.0 mL of the solution under test and dilute 7.5 mL of this solution with Buffer to 10.0 mL. Pass a portion of this solution through a PVDF filter of 0.45-μm pore size, discarding the first 5 mL. Replace the aliquot withdrawn for analysis with 13.0 mL of fresh Acid stage medium.

**Instrumental conditions**

(See Ultraviolet-Visible Spectroscopy (857).)

**Mode:** UV

**Analytical wavelength:** 276 nm

**Cell:** 1 cm

**Blank:** Buffer stage medium

**Analysis**

**Samples:** Acid stage standard solution and Acid stage sample solution

Calculate the percentage of the labeled amount of diclofenac sodium (C\(_\text{14}\)H\(_\text{13}\)Cl\(_\text{3}\)Na\(_\text{2}\)O\(_\text{2}\)) dissolved during the Acid stage:

\[
\text{Result} = \left( \frac{A_j}{A_i} \right) \times C_i \times V \times D \times \left( \frac{1}{1/L} \right) \times 100
\]

- \(A_j\) = absorbance of the Sample solution
- \(A_i\) = absorbance of the Standard solution
- \(C_i\) = concentration of USP Diclofenac Sodium RS in the Acid stage standard solution (mg/mL)
- \(V\) = volume of Acid stage medium, 750 mL
- \(D\) = dilution factor for the Acid stage sample solution, 1.33
- \(L\) = label claim for diclofenac sodium (mg/Tablet)

**Tolerances:** NMT 10% of the labeled amount of diclofenac sodium (C\(_\text{14}\)H\(_\text{13}\)Cl\(_\text{3}\)Na\(_\text{2}\)O\(_\text{2}\)) is dissolved. The percentage of the labeled amount of diclofenac sodium dissolved at the time specified conforms to Dissolution (711), Acceptance Table 3.

**Buffer stage**

- **Buffer stage standard stock solution:** 0.5 mg/mL of USP Diclofenac Sodium RS in Diluent
- **Buffer stage standard solution:** 0.02 mg/mL of USP Diclofenac Sodium RS in Buffer stage medium from the Buffer stage standard stock solution

**Buffer stage sample solution:** After 2 h of Acid stage dissolution, add 250 mL of Buffer to each vessel containing the remaining Tablets. Adjust, if necessary, with either 2 N hydrochloric acid or 2 N sodium hydroxide to a pH of 6.8 ± 0.1. After 60 min pass a portion of the solution under test through a PVDF filter of 0.45-μm pore size, discarding the first 5 mL.

Make dilutions with Buffer stage medium as necessary to obtain a solution of 0.02 mg/mL of diclofenac sodium.

**Instrumental conditions**

(See Ultraviolet-Visible Spectroscopy (857).)

**Mode:** UV

**Analytical wavelength:** 276 nm

**Cell:** 1 cm

**Blank:** Buffer stage medium

**Analysis**

**Samples:** Buffer stage standard solution and Buffer stage sample solution

Calculate the percentage of the labeled amount of diclofenac sodium (C\(_\text{14}\)H\(_\text{13}\)Cl\(_\text{3}\)Na\(_\text{2}\)O\(_\text{2}\)) dissolved during the Buffer stage:

\[
\text{Result} = \left( \frac{A_j}{A_i} \right) \times C_j \times V \times D \times \left( \frac{1}{1/L} \right) \times 100
\]

- \(A_j\) = absorbance of the Sample solution
- \(A_i\) = absorbance of the Standard solution
- \(C_j\) = concentration of USP Diclofenac Sodium RS in the Buffer stage standard solution (mg/mL)
- \(V\) = total volume of Buffer stage medium, 1000 mL
- \(D\) = dilution factor for the Buffer stage sample solution
- \(L\) = label claim for diclofenac sodium (mg/Tablet)

**Tolerances:** NLT 80% (Q) of the labeled amount of diclofenac sodium (C\(_\text{14}\)H\(_\text{13}\)Cl\(_\text{3}\)Na\(_\text{2}\)O\(_\text{2}\)) is dissolved. The percentage of the labeled amount of diclofenac sodium dissolved at the time specified conforms to Dissolution (711), Acceptance Table 3.

**Uniformity of Dosage Units** (905). Content Uniformity: Meet the requirements for diclofenac sodium and misoprostol

**Impurities**

- **Organic Impurities: Misoprostol**

**Buffer:** Prepare as directed in the Assay for Misoprostol.

**Solvent mixture:** Acetonitrile and methanol (26:28)

**Mobile phase:** Solvent mixture and Buffer (58:42)

**Diluent:** Acetonitrile and water (50:50)

**Standard stock solution:** Use the Standard solution prepared as directed in the Assay for Misoprostol.

**Standard solution:** 0.001 mg/mL of USP Misoprostol RS prepared as follows. Transfer 5 mL of the Standard stock solution to a 50-mL volumetric flask, and dilute with Diluent to volume.

**Sample solution:** Nominally 0.1 mg/mL of misoprostol prepared as follows. Using a quantity of Tablets equivalent to 2 mg of misoprostol, place 1 Tablet at a time on its edge inside a well-folded piece of weighing paper. Tap very carefully the edge of the Tablet with a pestle to separate the Tablet into the outer and inner layers. Remove the inner core containing diclofenac sodium. Fold back the outer layers of the Tablets containing misoprostol, and gently grind them. Transfer the ground outer layers into a 20-mL volumetric flask containing a magnetic stir bar, add 10 mL of acetonitrile, and stir the flask for 2 h. Allow the sample to stand for 10 min, transfer a portion of the solution into a glass centrifuge tube, and centrifuge for 10 min under refrigerated conditions (10°C). Transfer 2.5 mL of the supernatant into a 5-mL volumetric flask, and dilute with water to volume.

© The United States Pharmacopeial Convention All Rights Reserved.
Notice of Intent to Revise
Official: To Be Determined

Chromatographic system
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 200 and 280 nm
Column: 4.6-mm × 25-cm; 5-µm packing L7
Temperatures
   Autosampler: 10°
   Column: 35°
Flow rate: 0.6 mL/min
Injection volume: 100 µL
Run time: About 2.5 times the retention time of the misoprostol peak

System suitability
Sample: Standard solution at 200 nm
Suitability requirements
   Tailing factor: NMT 2
   Relative standard deviation: NMT 5.0%

Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of 8-epimisoprostol, A-type misoprostol, and any other individual impurity in the portion of Tablets taken:

$$\text{Result} = \left( \frac{r_0}{r_s} \right) \times \left( \frac{C_s}{C_u} \right) \times \left( \frac{1}{F} \right) \times 100$$

- $r_0$: peak response at 200 nm of any impurity from the Sample solution
- $r_s$: peak response at 200 nm of misoprostol from the Standard solution
- $C_s$: concentration of USP Misoprostol RS in the Standard solution (mg/mL)
- $C_u$: nominal concentration of misoprostol in the Sample solution (mg/mL)
- $F$: relative response factor (see Table 1)

Calculate the percentage of B-type misoprostol in the portion of Tablets taken:

$$\text{Result} = \left( \frac{r_0}{r_s} \right) \times \left( \frac{C_s}{C_u} \right) \times \left( \frac{1}{F} \right) \times 100$$

- $r_0$: peak response at 280 nm of B-type misoprostol from the Sample solution
- $r_s$: peak response at 200 nm of misoprostol from the Standard solution
- $C_s$: concentration of USP Misoprostol RS in the Standard solution (mg/mL)
- $C_u$: nominal concentration of misoprostol in the Sample solution (mg/mL)
- $F$: relative response factor (see Table 1)

Acceptance criteria: See Table 1.

### Table 1

<table>
<thead>
<tr>
<th>Name</th>
<th>Relative Retention Time</th>
<th>Relative Response Factor</th>
<th>Acceptance Criteria, NMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-Epiprostol</td>
<td>0.87</td>
<td>0.93</td>
<td>2.0%</td>
</tr>
<tr>
<td>Misoprostol</td>
<td>1.0</td>
<td>1.0</td>
<td>—</td>
</tr>
<tr>
<td>B-Type misoprostol</td>
<td>1.5</td>
<td>4.8</td>
<td>0.7</td>
</tr>
<tr>
<td>A-Type misoprostol</td>
<td>1.7</td>
<td>1.6</td>
<td>3.5</td>
</tr>
<tr>
<td>Any other individual impurity</td>
<td>—</td>
<td>1.0</td>
<td>0.6</td>
</tr>
<tr>
<td>Total misoprostol-related impurities</td>
<td>—</td>
<td>—</td>
<td>6.2</td>
</tr>
</tbody>
</table>

- $a$ Methyl(1$^R$,2$^R$,3$^R$)-3-hydroxy-2-[(E)-4-hydroxy-4-methyl-1-octenyl]-5-oxocyclopentaneheptanoate.
- $b$ 12-Epiprostone, which is a process impurity controlled in the drug substance, and 8-epimisoprostol are not separated by this method and should be integrated together to determine conformance.
- $c$ (E)-Methyl 7-[(4-hydroxy-4-methyl-1-enyl)-5-oxocyclopent-1-enyl]-heptanoate.
- $d$ Impurity peak response determined at 280 nm, quantitated against the misoprostol peak response determined at 200 nm.
- $e$ Methyl 7-[(R$^R$,S$^S$)-3-hydroxy-2-[(E)-4-hydroxy-4-methyl-1-octenyl]-5-oxocyclopentaneheptanoate.

• Organic Impurities: Diclofenac Sodium

Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system:
Proceed as directed in the Assay for Diclofenac Sodium.

Standard solution: 0.004 mg/mL of USP Diclofenac Related Compound A RS in Diluent

System suitability
Samples: System suitability solution and Standard solution
[NOTE—The relative retention times for diethyl phthalate, diclofenac related compound A, and diclofenac are about 0.6, 0.7, and 1.0, respectively.]

Suitability requirements
Resolution: NLT 2.2 between the diethyl phthalate and diclofenac related compound A peaks; NLT 6.5 between the diclofenac related compound A and diclofenac peaks, System suitability solution
Tailing factor: NMT 2, System suitability solution
Relative standard deviation: NMT 5.0%, Standard solution

Analysis
Samples: Sample solution and Standard solution
Calculate the percentage of diclofenac related compound A and any other individual impurity in the portion of Tablets taken:

$$\text{Result} = \left( \frac{r_0}{r_s} \right) \times \left( \frac{C_s}{C_u} \right) \times \left( \frac{1}{F} \right) \times 100$$

- $r_0$: peak response from the Sample solution
- $r_s$: peak response from the Standard solution
- $C_s$: concentration of USP Diclofenac Related Compound A RS in the Standard solution (mg/mL)
- $C_u$: nominal concentration of diclofenac sodium in the Sample solution (mg/mL)

Acceptance criteria
Diclofenac related compound A: NMT 0.5%
Any other individual impurity: NMT 0.2%
Total diclofenac-related impurities: NMT 1.0%

### ADDITIONAL REQUIREMENTS
• Packaging and Storage: Preserve in tight containers. Store at controlled room temperature.
Add the following:

* **LABELING**: When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 is not used.▲ (TBD)

**USP Reference Standards** (11)
- USP Diclofenac Sodium RS
- USP Diclofenac Related Compound A RS
- N-(2,6-Dichlorophenyl)indolin-2-one. \( \text{C}_{14}\text{H}_{9}\text{Cl}_{2}\text{NO} \) 278.14
- USP Misoprostol RS